Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089
Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
0
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study
https://www.zacks.com/stock/news/2243694/bayer-s-bayry-elinzanetant-meets-goals-in-third-phase-iii-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243694
Mar 20, 2024 - Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.
0
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839
Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
0
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
https://www.zacks.com/stock/news/2249692/after-plunging-7-94-in-4-weeks-here-s-why-the-trend-might-reverse-for-galapagos-glpg?cid=CS-ZC-FT-tale_of_the_tape|rsi-2249692
Apr 03, 2024 - The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
0
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
https://www.zacks.com/stock/news/2251537/fate-therapeutics-fate-surges-86-4-ytd-on-pipeline-progress?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251537
Apr 05, 2024 - Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
0
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Insulin Icodec
https://www.zacks.com/stock/news/2245039/novo-nordisk-nvo-gets-positive-chmp-opinion-for-insulin-icodec?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245039
Mar 22, 2024 - Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.
0
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
https://www.zacks.com/stock/news/2252898/bristol-myers-bmy-reports-positive-colorectal-cancer-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252898
Apr 09, 2024 - Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer.
0
Pages: 1
Page 1